Last 12 months
Inside the activity.
1 purchase rows · 28 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 15 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 11, 2026 00:51 UTC |
Pinto Daniel EDirector
|
GrantDeferred Share Units · Derivative | 113.098 | $276.31 | $31,250.11 |
DisclosureSEC source: 0000200406-26-000185 · wk-form4_1789087875.xml · derivative · entry 1 Pinto Daniel E · CIK 0001555174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,445.177 Underlying: Common Stock · 113.098 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 00:50 UTC |
Woods Eugene A.Director
|
GrantDeferred Share Units · Derivative | 135.717 | $276.31 | $37,499.96 |
DisclosureSEC source: 0000200406-26-000184 · wk-form4_1789087843.xml · derivative · entry 1 Woods Eugene A. · CIK 0001762647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,578.771 Underlying: Common Stock · 135.717 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 00:50 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 180.956 | $276.31 | $49,999.95 |
DisclosureSEC source: 0000200406-26-000183 · wk-form4_1789087809.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,049.417 Underlying: Common Stock · 180.956 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 13:08 UTC |
Schmid TimothyEVP, WW Chair, MedTech
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 22,527 | $0.00 Strike: $151.41 | $0.00 |
DisclosureSEC source: 0000200406-26-000179 · wk-form4_1788527285.xml · derivative · entry 8 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,527 shares Expires 2030-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 13:08 UTC |
Schmid TimothyEVP, WW Chair, MedTech
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 11,070 | $0.00 Strike: $131.94 | $0.00 |
DisclosureSEC source: 0000200406-26-000179 · wk-form4_1788527285.xml · derivative · entry 7 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,070 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 13:08 UTC |
Schmid TimothyEVP, WW Chair, MedTech
|
SaleCommon Stock | 22,527 | $274.74 | $6,189,067.98 |
DisclosureSEC source: 0000200406-26-000179 · wk-form4_1788527285.xml · nonDerivative · entry 4 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,447 Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 13:08 UTC |
Schmid TimothyEVP, WW Chair, MedTech
|
Exercise / conversionCommon Stock | 22,527 | $151.41 | $3,410,813.07 |
DisclosureSEC source: 0000200406-26-000179 · wk-form4_1788527285.xml · nonDerivative · entry 3 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 13:08 UTC |
Schmid TimothyEVP, WW Chair, MedTech
|
SaleCommon Stock | 11,070 | $274.74 | $3,041,371.80 |
DisclosureSEC source: 0000200406-26-000179 · wk-form4_1788527285.xml · nonDerivative · entry 2 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,447 Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 13:08 UTC |
Schmid TimothyEVP, WW Chair, MedTech
|
Exercise / conversionCommon Stock | 11,070 | $131.94 | $1,460,575.80 |
DisclosureSEC source: 0000200406-26-000179 · wk-form4_1788527285.xml · nonDerivative · entry 1 Schmid Timothy · CIK 0001998491 · EVP, WW Chair, MedTech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:31 UTC |
Taubert Jennifer LEVP, WWC. Innovative Medicine
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $115.67 | $0.00 |
DisclosureSEC source: 0000200406-26-000175 · wk-form4_1787092263.xml · derivative · entry 3 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,712 Underlying: Common Stock · 15,000 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:31 UTC |
Taubert Jennifer LEVP, WWC. Innovative Medicine
|
SaleCommon Stock | 15,000 | $263.36 | $3,950,400.00 |
DisclosureSEC source: 0000200406-26-000175 · wk-form4_1787092263.xml · nonDerivative · entry 2 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,451.001 F1 · price: This transaction was executed in multiple trades at prices ranging from $263.30 to $263.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:31 UTC |
Taubert Jennifer LEVP, WWC. Innovative Medicine
|
Exercise / conversionCommon Stock | 15,000 | $115.67 | $1,735,050.00 |
DisclosureSEC source: 0000200406-26-000175 · wk-form4_1787092263.xml · nonDerivative · entry 1 Taubert Jennifer L · CIK 0001745938 · EVP, WWC. Innovative Medicine 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,451.001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:35 UTC |
Duato JoaquinDirector · CEO and Chairman of the Board
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 123,291 | $0.00 Strike: $115.67 | $0.00 |
DisclosureSEC source: 0000200406-26-000173 · wk-form4_1786739711.xml · derivative · entry 6 Duato Joaquin · CIK 0001673401 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 123,291 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:35 UTC |
Duato JoaquinDirector · CEO and Chairman of the Board
|
SaleCommon Stock | 102,315 | $261.00 | $26,704,215.00 |
DisclosureSEC source: 0000200406-26-000173 · wk-form4_1786739711.xml · nonDerivative · entry 3 Duato Joaquin · CIK 0001673401 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,967 Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:35 UTC |
Duato JoaquinDirector · CEO and Chairman of the Board
|
SaleCommon Stock | 20,976 | $262.00 | $5,495,712.00 |
DisclosureSEC source: 0000200406-26-000173 · wk-form4_1786739711.xml · nonDerivative · entry 2 Duato Joaquin · CIK 0001673401 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,282 Read SEC document |
| August 13, 2026 Filed Aug 14, 2026 20:35 UTC |
Duato JoaquinDirector · CEO and Chairman of the Board
|
Exercise / conversionCommon Stock | 123,291 | $115.67 | $14,261,069.97 |
DisclosureSEC source: 0000200406-26-000173 · wk-form4_1786739711.xml · nonDerivative · entry 1 Duato Joaquin · CIK 0001673401 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 399,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 21:44 UTC |
Forminard ElizabethEVP, Chief Legal Officer
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 9,344 | $0.00 Strike: $131.94 | $0.00 |
DisclosureSEC source: 0000200406-26-000169 · wk-form4_1786139073.xml · derivative · entry 4 Forminard Elizabeth · CIK 0001950802 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,344 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 21:44 UTC |
Forminard ElizabethEVP, Chief Legal Officer
|
SaleCommon Stock | 6,574 | $255.93 | $1,682,496.97 |
DisclosureSEC source: 0000200406-26-000169 · wk-form4_1786139073.xml · nonDerivative · entry 3 Forminard Elizabeth · CIK 0001950802 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,994 Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 21:44 UTC |
Forminard ElizabethEVP, Chief Legal Officer
|
SaleCommon Stock | 9,344 | $257.76 | $2,408,462.72 |
DisclosureSEC source: 0000200406-26-000169 · wk-form4_1786139073.xml · nonDerivative · entry 2 Forminard Elizabeth · CIK 0001950802 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,568 Read SEC document |
| August 06, 2026 Filed Aug 7, 2026 21:44 UTC |
Forminard ElizabethEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 9,344 | $131.94 | $1,232,847.36 |
DisclosureSEC source: 0000200406-26-000169 · wk-form4_1786139073.xml · nonDerivative · entry 1 Forminard Elizabeth · CIK 0001950802 · EVP, Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:50 UTC |
Duato JoaquinDirector · CEO and Chairman of the Board
|
SaleCommon Stock | 6,523 | $258.74 | $1,687,754.50 |
DisclosureSEC source: 0000200406-26-000171 · wk-form4_1786139443.xml · nonDerivative · entry 2 Duato Joaquin · CIK 0001673401 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,967 F2 · price: This transaction was executed in multiple trades at prices ranging from $258.535 to $259.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:50 UTC |
Duato JoaquinDirector · CEO and Chairman of the Board
|
SaleCommon Stock | 41,957 | $258.06 | $10,827,255.59 |
DisclosureSEC source: 0000200406-26-000171 · wk-form4_1786139443.xml · nonDerivative · entry 1 Duato Joaquin · CIK 0001673401 · Director · CEO and Chairman of the Board 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 282,490 F1 · price: This transaction was executed in multiple trades at prices ranging from $257.53 to $258.505. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 21:27 UTC |
Broadhurst VanessaEVP, Global Corp Affairs
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 11,925 | $0.00 Strike: $131.94 | $0.00 |
DisclosureSEC source: 0000200406-26-000148 · wk-form4_1784669273.xml · derivative · entry 5 Broadhurst Vanessa · CIK 0001904787 · EVP, Global Corp Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,925 shares Expires 2029-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 21:27 UTC |
Broadhurst VanessaEVP, Global Corp Affairs
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 11,129 | $0.00 Strike: $129.51 | $0.00 |
DisclosureSEC source: 0000200406-26-000148 · wk-form4_1784669273.xml · derivative · entry 4 Broadhurst Vanessa · CIK 0001904787 · EVP, Global Corp Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,129 shares Expires 2028-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 21:27 UTC |
Broadhurst VanessaEVP, Global Corp Affairs
|
SaleCommon Stock | 23,054 | $251.27 | $5,792,686.36 |
DisclosureSEC source: 0000200406-26-000148 · wk-form4_1784669273.xml · nonDerivative · entry 3 Broadhurst Vanessa · CIK 0001904787 · EVP, Global Corp Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,003 F1 · price: This transaction was executed in multiple trades at prices ranging from $251.09 to $251.555. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 21:27 UTC |
Broadhurst VanessaEVP, Global Corp Affairs
|
Exercise / conversionCommon Stock | 11,925 | $131.94 | $1,573,384.50 |
DisclosureSEC source: 0000200406-26-000148 · wk-form4_1784669273.xml · nonDerivative · entry 2 Broadhurst Vanessa · CIK 0001904787 · EVP, Global Corp Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 21:27 UTC |
Broadhurst VanessaEVP, Global Corp Affairs
|
Exercise / conversionCommon Stock | 11,129 | $129.51 | $1,441,316.79 |
DisclosureSEC source: 0000200406-26-000148 · wk-form4_1784669273.xml · nonDerivative · entry 1 Broadhurst Vanessa · CIK 0001904787 · EVP, Global Corp Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:23 UTC |
Wengel Kathryn EEVP, Chief TO and Risk Officer
|
Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $115.67 | $0.00 |
DisclosureSEC source: 0000200406-26-000127 · wk-form4_1781299408.xml · derivative · entry 5 Wengel Kathryn E · CIK 0001745955 · EVP, Chief TO and Risk Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,965 Underlying: Common Stock · 10,000 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:23 UTC |
Wengel Kathryn EEVP, Chief TO and Risk Officer
|
SaleCommon Stock | 10,000 | $241.15 | $2,411,500.00 |
DisclosureSEC source: 0000200406-26-000127 · wk-form4_1781299408.xml · nonDerivative · entry 2 Wengel Kathryn E · CIK 0001745955 · EVP, Chief TO and Risk Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,287.8735 F1 · price: This transaction was executed in multiple trades at prices ranging from $240.14 to $240.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:23 UTC |
Wengel Kathryn EEVP, Chief TO and Risk Officer
|
Exercise / conversionCommon Stock | 10,000 | $115.67 | $1,156,700.00 |
DisclosureSEC source: 0000200406-26-000127 · wk-form4_1781299408.xml · nonDerivative · entry 1 Wengel Kathryn E · CIK 0001745955 · EVP, Chief TO and Risk Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,287.8735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:35 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 214.786 | $232.79 | $50,000.03 |
DisclosureSEC source: 0000200406-26-000121 · wk-form4_1781210156.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,791.877 Underlying: Common Stock · 214.786 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:43 UTC |
Pinto Daniel EDirector
|
GrantDeferred Share Units · Derivative | 134.241 | $232.79 | $31,249.96 |
DisclosureSEC source: 0000200406-26-000123 · wk-form4_1781210616.xml · derivative · entry 1 Pinto Daniel E · CIK 0001555174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,320.824 Underlying: Common Stock · 134.241 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:56 UTC |
Woods Eugene A.Director
|
GrantDeferred Share Units · Derivative | 161.089 | $232.79 | $37,499.91 |
DisclosureSEC source: 0000200406-26-000125 · wk-form4_1781211401.xml · derivative · entry 1 Woods Eugene A. · CIK 0001762647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,411.959 Underlying: Common Stock · 161.089 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:58 UTC |
REED JOHN CEVP, Innovative Medicine, R&D
|
Exercise / conversionRestricted Share Units · Derivative | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000115 · wk-form4_1777928336.xml · derivative · entry 3 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.exercise_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. F1 · derivative.expiration_date: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:58 UTC |
REED JOHN CEVP, Innovative Medicine, R&D
|
Tax withholdingCommon Stock | 11,002 | $229.85 | $2,528,809.70 |
DisclosureSEC source: 0000200406-26-000115 · wk-form4_1777928336.xml · nonDerivative · entry 2 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,911 F2 · shares: Shares withheld for payment of taxes upon vesting of RSUs. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:58 UTC |
REED JOHN CEVP, Innovative Medicine, R&D
|
Exercise / conversionCommon Stock | 25,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000115 · wk-form4_1777928336.xml · nonDerivative · entry 1 REED JOHN C · CIK 0001181561 · EVP, Innovative Medicine, R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on May 1, 2023 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:38 UTC |
Beckerle Mary CDirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000092 · wk-form4_1777325899.xml · derivative · entry 1 Beckerle Mary C · CIK 0001520181 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,797.7393 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:43 UTC |
Doudna Jennifer ADirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000094 · wk-form4_1777326205.xml · derivative · entry 1 Doudna Jennifer A · CIK 0001739090 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,899.1714 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 21:48 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000096 · wk-form4_1777326520.xml · derivative · entry 1 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,487.939 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:01 UTC |
Johnson Paula ADirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000098 · wk-form4_1777327261.xml · derivative · entry 1 Johnson Paula A · CIK 0001341161 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,359.3973 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:05 UTC |
Joly HubertDirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000100 · wk-form4_1777327547.xml · derivative · entry 1 Joly Hubert · CIK 0001467638 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,183.605 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:06 UTC |
McClellan Mark B.Director
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000102 · wk-form4_1777327601.xml · derivative · entry 1 McClellan Mark B. · CIK 0001567006 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,278.593 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:12 UTC |
MORIKIS JOHN GDirector
|
GrantDeferred Share Units · Derivative | 1,540 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000104 · wk-form4_1777327934.xml · derivative · entry 1 MORIKIS JOHN G · CIK 0001203523 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,540 Underlying: Common Stock · 1,540 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:13 UTC |
Pinto Daniel EDirector
|
GrantDeferred Share Units · Derivative | 1,712 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000106 · wk-form4_1777328012.xml · derivative · entry 1 Pinto Daniel E · CIK 0001555174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,174.069 Underlying: Common Stock · 1,712 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:17 UTC |
WEINBERGER MARK ADirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000108 · wk-form4_1777328237.xml · derivative · entry 1 WEINBERGER MARK A · CIK 0001785997 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,010.408 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:21 UTC |
West NadjaDirector
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000111 · wk-form4_1777328506.xml · derivative · entry 1 West Nadja · CIK 0001787802 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,730.0491 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| April 23, 2026 Filed Apr 27, 2026 22:23 UTC |
Woods Eugene A.Director
|
GrantDeferred Share Units · Derivative | 975 | $0.00 | $0.00 |
DisclosureSEC source: 0000200406-26-000113 · wk-form4_1777328617.xml · derivative · entry 1 Woods Eugene A. · CIK 0001762647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,215.094 Underlying: Common Stock · 975 shares Expires not disclosed F1 · derivative.exercise_price: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.exercise_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F1 · derivative.expiration_date: Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date). F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 13, 2026 00:37 UTC |
Woods Eugene A.Director
|
GrantDeferred Share Units · Derivative | 154.869 | $242.14 | $37,499.98 |
DisclosureSEC source: 0000200406-26-000067 · wk-form4_1773362248.xml · derivative · entry 1 Woods Eugene A. · CIK 0001762647 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,240.094 Underlying: Common Stock · 154.869 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 13, 2026 00:39 UTC |
Pinto Daniel EDirector
|
GrantDeferred Share Units · Derivative | 129.058 | $242.14 | $31,250.10 |
DisclosureSEC source: 0000200406-26-000069 · wk-form4_1773362378.xml · derivative · entry 1 Pinto Daniel E · CIK 0001555174 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462.069 Underlying: Common Stock · 129.058 shares Expires not disclosed F1 · derivative.exercise_price: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.exercise_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F1 · derivative.expiration_date: Acquisition of Deferred Share Units (DSU) for deferral of cash retainer under the Issuer's Amended and Restated Deferred Fee Plan for Directors. DSUs are to be settled in cash upon termination of the Reporting Person's directorship. Each DSU represents the fair market value of one share of Common Stock on the business day prior to settlement date. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 13, 2026 01:31 UTC |
HEWSON MARILLYN ADirector
|
GrantDeferred Share Units · Derivative | 206.492 | $242.14 | $49,999.97 |
DisclosureSEC source: 0000200406-26-000070 · wk-form4_1773365486.xml · derivative · entry 2 HEWSON MARILLYN A · CIK 0001217496 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,512.94 Underlying: Common Stock · 206.492 shares Expires not disclosed F3 · derivative.exercise_price: Acquisition of DSUs for deferral of cash retainer under the Plan. F3 · derivative.exercise_date: Acquisition of DSUs for deferral of cash retainer under the Plan. F3 · derivative.expiration_date: Acquisition of DSUs for deferral of cash retainer under the Plan. F2 · balance_after: Includes dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on DSUs held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.